Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses (Addendum, 2003, to the Recommendations for the Production and Quality Control of Poliomyelitis Vaccine (Inactivated)
WHO collaborative study to establish a replacement International Standard for anti-poliovirus sera, Expert Committee on Biological Standardization, Geneva, 22-29 October 1991
Report of a collaborative study to assess the suitability of a replacement International Standard for Oral Polio Vaccine, Expert Committee on Biological Standardization, Geneva, 15-19 November 2004
Proposal to establish an International Standard for MAPREC analysis of poliovirus type 3 (Sabin)
Expert Committee on Biological Standardization, Geneva, 7-11 October 1996
WHO Implementation Workshop: Characterization of cell banks for the production of biologicals, 27-29 May 2013 and WHO Informal Consultation on regulatory risk assessment in the case of adventitious agent finding in a marketed vaccine, 30-31 May 2013, Beijing, Republic of China
WHO Informal Consultation on the Scientific and Regulatory Considerations on the Stability Evaluation of Vaccines under a Controlled Temperature Chain, Langen, Germany, 4-6 June 2013
Expert Committee on Biological Standardization, Geneva, Switzerland, 21-25 October 2013
CONTACTS
Quality, Safety and Standards (QSS)
Immunization, Vaccines and Biologicals (IVB)
World Health Organization (WHO)
Avenue Appia 20
1211 Geneva 27, Switzerland
Fax No. +41 22 7914971
